Angiotensin-Converting Enzyme Inhibitors in Coronary Artery Disease and Preserved Left Ventricular Systolic Function. A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Journal of the American College of Cardiology

Volumn 47, Issue 8, 2006, Pages 1576-1583

  Al Mallah, Mouaz H ^a   Tleyjeh, Imad M ^b   Abdel Latif, Ahmed A ^c   Weaver, W Douglas ^a  

^a HENRY FORD HEART AND VASCULAR INSTITUTE   (United States)

^b Mayo Clinic   (United States)

^c UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLACEBO;

ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CORONARY ARTERY DISEASE; DEATH; HEART INFARCTION; HEART LEFT VENTRICLE CONTRACTION; HEART MUSCLE REVASCULARIZATION; HUMAN; MEDICAL RESEARCH; META ANALYSIS; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK FACTOR; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CORONARY ARTERIOSCLEROSIS; HUMANS; RANDOMIZED CONTROLLED TRIALS; SYSTOLE; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 33646040116     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2005.11.073     Document Type: Article

References (39)

1. Staessen J., Wang J., and Thijs L. Cardiovascular protection and blood pressure reduction. a meta-analysis. Lancet 358 (2001) 1305-1315
2. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events. results of prospectively designed overviews of randomised trials. Lancet 362 (2003) 1527-1535
3. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs. results of prospectively designed overviews of randomized trials. Lancet 356 (2000) 1955-1964
4. Fourth International Study of Infarct Survival Collaborative Group. A randomized factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4. Lancet 345 (1995) 669-685
5. GISSI-3 Investigators, and Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 343 (1994) 1115
6. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 342 (1993) 821-828
7. Ambrosioni E., Borghi C., Magnani B., and Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. The effect of the angiotensin-converting enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med 332 (1995) 80-85
8. Pfeffer M.A., Greaves S.C., Arnold M.O., et al., Healing and Early Afterload Reducing Therapy (HEART) Trial Investigators. Early versus delayed angiotension-converting enzyme inhibition therapy in acute myocardial infarction. The Healing and Early Afterload Reducing Therapy Trial. Circulation 95 (1997) 2643-2651
9. Otsuka M., Yamamoto H., Okimoto T., et al. Long-term effects of quinapril with high affinity for tissue angiotensin-converting enzyme after coronary intervention in Japanese. Am Heart J 147 (2004) 662-668
10. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 316 (1987) 1429-1435
11. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325 (1991) 293-302
12. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 327 (1992) 685-691
13. Kober L., Torp-Pedersen C., Carlsen J.E., et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 333 (1995) 1670-1676
14. Flather M.D., Yusuf S., Kober L., et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction. a systematic overview of data from individual patients. Lancet 355 (2000) 1575-1581
15. Pfeffer M.A., Braunwald E., Moyeé L.A., et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. results of the Survival and Ventricular Enlargement Trial. N Engl J Med 327 (1992) 669-677
16. Yusuf S., Pepine C.J., Garces C., et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 340 (1992) 1173-1178
17. Rutherford J.D., Pfeffer M.A., Moyeé L.A., et al. Effects of captopril on ischemic events after myocardial infarction. results of the Survival and Ventricular Enlargement trial. Circulation 90 (1994) 1731-1738
18. Antman E.M., Anbe D.T., Armstrong P.W., et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: executive summary: a report of the ACC/AHA Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines on the Management of Patients With Acute Myocardial Infarction). J Am Coll Cardiol 44 (2004) 671-719
19. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342 (2000) 145-153
20. Dagenais G., Yusuf S., Bourassa M., et al. Effects of ramipril on coronary events in high-risk persons. results of the Heart Outcomes Prevention Evaluation Study. Circulation 104 (2001) 522-526
21. Fox K.M., and European Trial on Reduction of Cardiac Events with Perindopril in Stable Coronary Artery Disease Investigators. Efficacy on perindopril in reduction of cardiovascular events among patients with stable coronary artery disease. randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 362 (2003) 782-788
22. The PEACE Trial Investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 351 (2004) 2058-2068
23. Pitt B. ACE inhibitors for patients with vascular disease without left ventricular dysfunction-may they rest in PEACE?. N Engl J Med 351 (2004) 2115-2117
24. Pitt B., O'Neill B., Feldman R., et al. The Quinapril Ischemic Event Trial (QUIET). evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function. Am J Cardiol 87 (2001) 1058-1063
25. Nissen S., Tuzcu M., Libby P., et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 292 (2004) 2217-2225
26. MacMahon S., Sharpe N., Gamble G., et al. Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. J Am Coll Cardiol 36 (2000) 438-443
27. Jüni P., Altman D., and Egger M. Systematic reviews in health care. assessing the quality of controlled clinical trials. BMJ 323 (2001) 42-46
28. DerSimonian R., and Laird N. Meta-analysis in clinical trials. Control Clin Trials 7 (1986) 177-188
29. Higgins J.P., Thompson S.G., Deeks J.J., and Altman D.G. Measuring inconsistency in meta-analyses. BMJ 327 (2003) 557-560
30. Altman D.G., and Bland J.M. Interaction revisited. the difference between two estimates. BMJ 326 (2003) 25
31. Schlaifer J.D., Mancini G.B., O'Neill B.J., et al. Influence of smoking status on angiotensin-converting enzyme inhibition-related improvement in coronary endothelial function. Cardiovasc Drugs Ther 13 (1999) 201-209
32. Dzau V.J., Bernstein K., Celermajer D., et al. Pathophysiologic and therapeutic importance of tissue ACE. a consensus report. Cardiovasc Drugs Ther 16 (2002) 149-160
33. Dzau V.J. Mechanism of protective effects of ACE inhibition on coronary artery disease. Eur Heart J 19 Suppl J (1998) J2-J6
34. Mancini G.B., Henry G.C., Macaya C., et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation 94 (1996) 258-265
35. Yusuf S., Pogue J., Myers M., et al. ACE inhibition in stable coronary artery disease. N Engl J Med 352 (2005) 937-939
36. Wagner A.H., Kohler T., Ruckschloss U., et al. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol 20 (2000) 61-69
37. Griendling K.K., Minieri C.A., Ollerenshaw J.D., et al. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 74 (1994) 1141-1148
38. Abuissa H., Jones P., Marso S., et al. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes. a meta-analysis of randomized clinical trials. J Am Coll Cardiol 46 (2005) 821-826
39. Healey J., Baranchuk A., and Crystal E. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. a meta-analysis. at al. J Am Coll Cardiol 45 (2005) 1831-1837